ATE500845T1 - Anthracyclin-anti-cd74-antikörperkonjugate - Google Patents
Anthracyclin-anti-cd74-antikörperkonjugateInfo
- Publication number
- ATE500845T1 ATE500845T1 AT04703628T AT04703628T ATE500845T1 AT E500845 T1 ATE500845 T1 AT E500845T1 AT 04703628 T AT04703628 T AT 04703628T AT 04703628 T AT04703628 T AT 04703628T AT E500845 T1 ATE500845 T1 AT E500845T1
- Authority
- AT
- Austria
- Prior art keywords
- anthracycline
- conjugates
- chemotherapeutic drug
- targeting antibody
- antibodies conjugates
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44212503P | 2003-01-24 | 2003-01-24 | |
| PCT/US2004/001367 WO2004067038A1 (en) | 2003-01-24 | 2004-01-20 | Anthracycline-antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500845T1 true ATE500845T1 (de) | 2011-03-15 |
Family
ID=32825184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04703628T ATE500845T1 (de) | 2003-01-24 | 2004-01-20 | Anthracyclin-anti-cd74-antikörperkonjugate |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20040202666A1 (de) |
| EP (1) | EP1594548B1 (de) |
| JP (2) | JP4805137B2 (de) |
| KR (1) | KR101053739B1 (de) |
| CN (1) | CN1764478B (de) |
| AT (1) | ATE500845T1 (de) |
| AU (2) | AU2004207494C1 (de) |
| BR (1) | BRPI0406574A (de) |
| CA (1) | CA2510664C (de) |
| DE (1) | DE602004031714D1 (de) |
| IL (1) | IL169769A (de) |
| MX (1) | MXPA05007851A (de) |
| PL (1) | PL378012A1 (de) |
| RU (1) | RU2349343C2 (de) |
| WO (1) | WO2004067038A1 (de) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| DK1392359T4 (da) | 2001-05-11 | 2013-06-10 | Ludwig Inst For Cancer Res Ltd | Specifikke bindingsproteiner og deres anvendelser. |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8148335B2 (en) * | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| JP5618549B2 (ja) | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤 |
| CA2682851C (en) | 2007-04-02 | 2017-01-17 | Philogen S.P.A. | A novel antigen associated with the neovasculature of tumour metastases |
| WO2008151819A2 (en) | 2007-06-15 | 2008-12-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Treatment of tumors using specific anti-l1 antibody |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途 |
| EP2209805B1 (de) | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | Mit rheumatoider arthritis assoziiertes antigen |
| JP5476310B2 (ja) * | 2008-02-14 | 2014-04-23 | 株式会社イーベック | ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物 |
| RU2485969C2 (ru) * | 2008-04-16 | 2013-06-27 | Юнайтед Текнолоджис Ут Аг | Способ определения композиций, способных стимулировать образование стволовых клеток в коже |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| AU2009270988A1 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| EP2379116B1 (de) | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Mit endometriose assoziierte antigene |
| PL3912643T3 (pl) | 2009-02-13 | 2023-01-23 | Immunomedics Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| WO2013009475A1 (en) * | 2011-07-11 | 2013-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Photosensitizing antibody-phuorophore conjugates |
| CN102258789B (zh) * | 2010-12-29 | 2013-04-24 | 海南医学院 | 小型化Endoglin抗体与阿霉素的偶联物及其制备方法 |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| EP2589609A1 (de) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs |
| WO2013130963A1 (en) | 2012-03-02 | 2013-09-06 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating type iii gaucher disease |
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3135690A1 (de) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| EP2903629B1 (de) | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antikörperkonjugat zur verwendung bei der behandlung von entzündlichen darmerkrankungen |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (de) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| US8877202B2 (en) * | 2013-02-07 | 2014-11-04 | Immunomedics, Inc. | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| CN110251683A (zh) * | 2013-06-24 | 2019-09-20 | Abl生物公司 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| CA2920192A1 (en) * | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
| SG10201902571VA (en) * | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| ES2978993T3 (es) | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| US12685781B2 (en) | 2014-04-10 | 2026-07-21 | Daiichi Sankyo Company, Limited | Anti-HER3 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| CA2954463C (en) | 2014-08-08 | 2023-11-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photo-controlled removal of targets in vitro and in vivo |
| US10149913B2 (en) * | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| EP3200822B1 (de) | 2014-09-30 | 2021-04-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Bindungsmoleküle, insbesondere antikörper die sich an l1cam (cd171) binden |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| EP3286224A4 (de) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| CN121270700A (zh) | 2015-08-07 | 2026-01-06 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit) |
| ES2999358T3 (en) | 2015-08-18 | 2025-02-25 | Rakuten Medical Inc | Phthalocyanine dye conjugates and their storage |
| ES2992591T3 (en) | 2015-08-18 | 2024-12-16 | Rakuten Medical Inc | Compositions, combinations and related methods for photoimmunotherapy |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| AU2017212739B2 (en) | 2016-01-27 | 2024-03-21 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| WO2017207540A1 (en) | 2016-05-30 | 2017-12-07 | Toxinvent Oü | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| WO2018115485A1 (en) | 2016-12-22 | 2018-06-28 | Pierfrancesco Tassone | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| EP3677589B1 (de) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Verbessertes verfahren zur herstellung eines antikörper-wirkstoff-konjugats |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| EP3794042B1 (de) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Conjugue agent cytotoxique et anticorps anti-muc1-exatecan |
| AU2018431586B2 (en) * | 2018-07-09 | 2025-03-20 | Synthis Therapeutics, Inc | Antibody-ALK5 inhibitor conjugates and their uses |
| EP3831853A4 (de) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | Protein-erkennende arzneimitteleinheit eines antikörper-wirkstoff-konjugats |
| IL325918A (en) | 2018-07-31 | 2026-03-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates for use in the treatment of metastatic brain tumor |
| CN109761427B (zh) * | 2019-03-04 | 2021-07-20 | 南京信息工程大学 | 一种生产石墨烯工厂产生的污水的资源化方法 |
| US12704501B2 (en) | 2019-03-29 | 2026-08-11 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
| WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
| EP4342497A1 (de) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antikörper mit reduzierter bindungsaffinität für antigen |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| CA2048089A1 (en) * | 1990-09-17 | 1992-03-18 | Wolfgang A. Wrasidlo | Chemical conjugation of morpholino anthracyclines to antibodies |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| EP0871490B1 (de) * | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Verzweigte hydrazongruppen enthaltende kuppler |
| DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| EP1383544A4 (de) * | 2001-04-09 | 2007-12-12 | Progenics Pharm Inc | Anti-cd19-immunotoxine |
| WO2002092127A1 (en) * | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-ｃｄ74 항체 및 그 이용방법 |
-
2004
- 2004-01-15 US US10/757,543 patent/US20040202666A1/en not_active Abandoned
- 2004-01-20 MX MXPA05007851A patent/MXPA05007851A/es active IP Right Grant
- 2004-01-20 CN CN200480007880.XA patent/CN1764478B/zh not_active Expired - Fee Related
- 2004-01-20 AT AT04703628T patent/ATE500845T1/de not_active IP Right Cessation
- 2004-01-20 PL PL378012A patent/PL378012A1/pl unknown
- 2004-01-20 CA CA2510664A patent/CA2510664C/en not_active Expired - Fee Related
- 2004-01-20 WO PCT/US2004/001367 patent/WO2004067038A1/en not_active Ceased
- 2004-01-20 BR BR0406574-3A patent/BRPI0406574A/pt not_active Application Discontinuation
- 2004-01-20 JP JP2006502890A patent/JP4805137B2/ja not_active Expired - Fee Related
- 2004-01-20 RU RU2005126717/15A patent/RU2349343C2/ru not_active IP Right Cessation
- 2004-01-20 AU AU2004207494A patent/AU2004207494C1/en not_active Ceased
- 2004-01-20 EP EP04703628A patent/EP1594548B1/de not_active Expired - Lifetime
- 2004-01-20 KR KR1020057013686A patent/KR101053739B1/ko not_active Expired - Fee Related
- 2004-01-20 DE DE602004031714T patent/DE602004031714D1/de not_active Expired - Lifetime
-
2005
- 2005-05-26 US US11/137,385 patent/US20050271671A1/en not_active Abandoned
- 2005-07-19 IL IL169769A patent/IL169769A/en active IP Right Grant
-
2009
- 2009-08-26 AU AU2009212806A patent/AU2009212806B2/en not_active Ceased
-
2010
- 2010-10-18 JP JP2010233918A patent/JP5501927B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011012083A (ja) | 2011-01-20 |
| JP5501927B2 (ja) | 2014-05-28 |
| CA2510664A1 (en) | 2004-08-12 |
| US20050271671A1 (en) | 2005-12-08 |
| KR20050104354A (ko) | 2005-11-02 |
| IL169769A (en) | 2011-11-30 |
| RU2349343C2 (ru) | 2009-03-20 |
| AU2004207494A1 (en) | 2004-08-12 |
| CN1764478B (zh) | 2015-10-21 |
| RU2005126717A (ru) | 2006-02-10 |
| WO2004067038A1 (en) | 2004-08-12 |
| BRPI0406574A (pt) | 2006-01-17 |
| KR101053739B1 (ko) | 2011-08-02 |
| DE602004031714D1 (de) | 2011-04-21 |
| JP4805137B2 (ja) | 2011-11-02 |
| US20040202666A1 (en) | 2004-10-14 |
| EP1594548B1 (de) | 2011-03-09 |
| MXPA05007851A (es) | 2005-10-18 |
| AU2004207494C1 (en) | 2009-11-05 |
| AU2009212806B2 (en) | 2011-12-08 |
| AU2004207494B2 (en) | 2009-05-28 |
| JP2006515892A (ja) | 2006-06-08 |
| CA2510664C (en) | 2012-04-17 |
| EP1594548A1 (de) | 2005-11-16 |
| CN1764478A (zh) | 2006-04-26 |
| PL378012A1 (pl) | 2006-02-20 |
| AU2009212806A1 (en) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004031714D1 (de) | Anthracyclin-anti-cd74-antikörperkonjugate | |
| WO2005032454A3 (en) | Anti-muc-1 single chain antibodies for tumor targeting | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| TW200607523A (en) | Drug compositions, fusions and conjugates | |
| CY1123400T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| NO20072670L (no) | PLAD domene peptider med okt halveringstid i serum pa grunn av konjugering til domene antistoffer | |
| NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
| EP2684889A3 (de) | Mit einem zielgerichteten menschlichen monoklonalen Antikörper komplexierte multivariable Antigene | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| WO2004010957A3 (en) | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | |
| IL176940A (en) | An isolated antibody or antigen-binding fragment thereof | |
| WO2007112193A3 (en) | Camptothecin-binding moiety conjugates | |
| EA200600275A1 (ru) | Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения | |
| EA011859B9 (ru) | Соединения для адресной доставки препарата к ткани или органу-мишени | |
| NO20083127L (no) | Fremgangsmater og preparater for malretting av polyubiquitin | |
| CY1118053T1 (el) | Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea | |
| EP1871417A4 (de) | Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom | |
| AU9399501A (en) | Therapeutic antibodies | |
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| CY2014002I1 (el) | Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων | |
| ATE455127T1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
| MY209779A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| BRPI0411854A (pt) | veìculos protéicos para vacinas | |
| GB2383331A (en) | Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |